Cathie Wood is loading up on shares of a biotech that could be one of the first entrants to the psychedelics market.

COMPASS Pathways leads regulated psilocybin with two successful Phase 3 trials and a rolling FDA submission. Read why CMPS ...

When the VA announced its first-ever MDMA-assisted therapy clinical trial for veterans with PTSD this spring, it was treated, ...

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that it will release financial results ...

We recently compiled a list of the 7 Best Psychedelic Stocks to Buy According to Analysts. COMPASS Pathways plc (NASDAQ:CMPS) is one of the best psychedelic stocks on our list. TheFly reported on July ...

Eli Lilly's acquisition of AtaiBeckley for up to $3.8 billion, marks a pivotal moment for psychedelic medicine.

Insider trading activity involves company insiders, such as executives, directors, and employees, engaging in transactions of their own company's stock. Insiders' buy and sell transactions provide ...

Earlier in July 2026, COMPASS Pathways reported 26-week data from its second Phase 3 COMP006 trial of COMP360 psilocybin in treatment-resistant depression, showing rapid onset, durable clinical ...

LONDON & NEW YORK--(BUSINESS WIRE)--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today reported ...

Some of the most important upcoming catalysts for Compass' stock have little to do with its own research and development (R&D) or business development activities. Lykos Therapeutics, a psychedelic ...